Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Clinical Trials Resume After COVID-19 Disruption
When the COVID-19 pandemic struck earlier this year, clinical trials at medical centers around the world slowed enrollment or placed trial activities on hold. As businesses begin to reopen in the United States, more treatment centers are resuming mesothelioma study activities and ramping up enrollment. Clinical research trials offer patients access to experimental mesothelioma treatments that haven’t yet been approved by the U.S. Food and Drug Administration. These treatments may provide higher chances of survival than the current standard of care. “So far, every patient I have seen during the COVID-19 pande...
Source: Asbestos and Mesothelioma News - August 10, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

MD Anderson Leads List of Top-Tier Cancer Hospitals
For the sixth consecutive year, University of Texas MD Anderson Cancer Center in Houston was named the top Adult Cancer Hospital in America by U.S. News & World Report. Several of the top-tier cancer centers on the list have specialty programs for mesothelioma that contributed to their high ranking. The 2020-21 Best Hospitals for Cancer rankings, announced this week, are part of a broader Best Hospitals Honor Roll done annually by U.S. News & World Report. Top five cancer center rankings also included Memorial Sloan Kettering in New York City; Mayo Clinic in Rochester, Minnesota; Johns Hopkins Hospital in Baltimore...
Source: Asbestos and Mesothelioma News - July 29, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study Shows Peritoneal Mesothelioma Surgery Underutilized
The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from, the highly effective procedure. Only a third of those diagnosed with peritoneal mesothelioma are undergoing potentially curative cytoreductive mesothelioma surgery, according to a comprehensive study of the National Cancer Database by researchers at Inova Fairfax Medical Center in Virginia. Annals of Surgical Oncology published the mesothelioma study earlier this year. “Patients who have the surgery perform much better than those who do not. Ye...
Source: Asbestos and Mesothelioma News - July 28, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Merck, Targovax Team Up for New Mesothelioma Clinical Trial
Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between...
Source: Asbestos and Mesothelioma News - July 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

More Mesothelioma Cancer Centers Using Tumor Treating Fields
Tumor Treating Fields is one of the newest treatments on the market for pleural mesothelioma cancer patients with metastatic disease. The device is also available to patients with locally advanced cancer who are not candidates for mesothelioma surgery. Clinical trials of the treatment, previously known as NovoTTF-100L, extended the survival of mesothelioma patients by more than six months compared to those receiving only chemotherapy. The device is now called Optune Lua and has been available outside of clinical trials for over a year. More physicians and treatment centers are becoming certified to prescribe the treatmen...
Source: Asbestos and Mesothelioma News - July 21, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Leaving Libby After Massive Asbestos Cleanup
Mike Cirian came to Libby, Montana, in 2005 to lead the largest asbestos cleanup project in American history, a decontamination effort of unprecedented proportion. He never left. Cirian helped turn a dark, deadly past into a much brighter, celebrated future. As manager of the EPA’s asbestos Superfund site ­– stemming from the massive asbestos-contaminated vermiculite mine that killed hundreds and sickened thousands – Cirian is nearing the end of his role. On July 1, the U.S. Environmental Protection Agency officially transferred oversight and responsibility for much of the sprawling project to the Mon...
Source: Asbestos and Mesothelioma News - July 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Nonprofits Call for Worldwide Halt of J & J Baby Powder Sales
National advocacy group Black Women for Wellness joined more than 170 other nonprofits from 51 countries last week in demanding that Johnson & Johnson stop the worldwide distribution of its iconic Johnson’s Baby Powder. The demand for a global distribution ban stems from the potential for asbestos in talc, which has led to various cancers and thousands of personal injury lawsuits. A majority of talc cases pertain to women and ovarian cancer. A small percentage of the legal claims involve mesothelioma, a rare and aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Johnson & Jo...
Source: Asbestos and Mesothelioma News - July 13, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

NCI Studying New Mesothelioma Immunotherapy Combination
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - July 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rise in Talc Cases Reshapes Traditional Asbestos Litigation
A recent rise in litigation linking cosmetic talc with mesothelioma and lung cancer will continue throughout 2020, despite companies abandoning the product in the hope of avoiding costly verdicts. The number of legal cases is expected to increase by 10% this year, building on an 11% rise in 2019, according to KCIC, a well-regarded consulting firm based in Washington, D.C., that manages asbestos product liabilities. “A new trend we have started to see is talc allegations showing up in traditional asbestos complaints,” said KCIC Vice President Michelle Potter during a recent webinar that looked at past litigation...
Source: Asbestos and Mesothelioma News - July 7, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Cryoablation Study for Mesothelioma Opening at UCLA
Researchers at UCLA Jonsson Comprehensive Cancer Center will soon begin studying the pre-surgery use of cryoablation as a potential early adjuvant therapy for patients with pleural mesothelioma. The pilot study will measure immune system stimulation through local tumor infiltration in hopes of extending patient survival in the future. Cryoablation, also known as cryotherapy or cryosurgery, freezes localized tumors with liquid nitrogen or argon gas. It has been proven effective in killing tumor cells with extreme cold. It is currently used on kidney, liver and prostate cancers, but its use in priming a person’s own i...
Source: Asbestos and Mesothelioma News - July 1, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Talc-Asbestos Verdict Upheld, Award Cut
The Missouri Court of Appeals upheld a landmark jury verdict that said long-term use of Johnson & Johnson’s talc products, possibly contaminated with asbestos fibers, had caused ovarian cancer in 22 women. The Court of Appeals also reduced the earlier, record-setting award for punitive and compensatory damages from $4.69 billion to $2.1 billion. A Johnson & Johnson spokesperson said the company would appeal again with the Supreme Court of Missouri. Johnson & Johnson has been flooded with more than 19,000 lawsuits in U.S. state and federal courts over its talc products, the majority of which pertain to ova...
Source: Asbestos and Mesothelioma News - June 25, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Tazemetostat Shows Promise for Pleural Mesothelioma
Five different research groups at the American Society of Clinical Oncology annual meeting last month made presentations on the effectiveness of tazemetostat, a novel protein inhibitor, in fighting various cancers. Pleural mesothelioma was one of those cancers in which clear efficacy was demonstrated, raising hopes again for a future second-line therapy option. “It wasn’t the breakthrough you may be looking for, but there is a set of patients now that can benefit from this treatment for a period of time,” Dr. Marianna Koczywas, medical oncologist at City of Hope cancer treatment and research center in Cal...
Source: Asbestos and Mesothelioma News - June 24, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Chemoperfusion Trial Shows Impressive Results
Study statistics show the benefits of the novel transarterial chemoperfusion treatment being used successfully at the Moffitt Cancer Center in Tampa for patients with relapsed pleural mesothelioma. Russell Lamkins — working on the roof of a neighbor’s house — shows them even better. He is living proof. This latest mesothelioma treatment has potential. Lamkins, 73, was first diagnosed with mesothelioma in 2014. He was the second patient to enroll in the mesothelioma clinical trial in March 2016, soon after standard-of-care chemotherapy and immunotherapy had failed him. “At that point, I had no choice...
Source: Asbestos and Mesothelioma News - June 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

FDA Approves Keytruda for Certain Mesothelioma Patients
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - June 17, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study Finds Mesothelioma Therapies Underutilized in Women
A multicenter research team of specialists has uncovered a surprising underutilization of treatments for pleural mesothelioma cancer in women. Clinical Lung Cancer recently published the findings, which showed a significant sex-based disparity in the receipt of care for women when compared with that of men. Women were 15% less likely to receive aggressive mesothelioma surgery that has proven its worth in extending lives for this cancer, which has no definitive cure. They also were 20% less likely to receive chemotherapy than were men. “This is concerning, absolutely,” Dr. Charles Simone, chief medical officer a...
Source: Asbestos and Mesothelioma News - June 15, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Major Cosmetic Companies Moving Away from Talc in Makeup
Consumer concerns and the threat of potentially costly lawsuits are driving cosmetic companies away from the long-standing manufacture of talc-based products. Reuters News Service is reporting that Revlon, Chanel and L’Oreal — three of the biggest names in U.S. cosmetics — have been turning quietly to talc alternatives in the last few years. Talc is the softest mineral on Earth and is used ubiquitously in thousands of personal care and cosmetic products to absorb moisture, provide lubrication and improve feel. Unfortunately, talc also is mined near the Earth’s surface in proximity to asbestos, which...
Source: Asbestos and Mesothelioma News - June 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ramucirumab Shows Promise in Mesothelioma Clinical Trial
Patients with pleural mesothelioma cancer experienced a significant survival advantage when ramucirumab, a novel immunotherapy drug, was added to chemotherapy in a treatment regimen. Ramucirumab, marketed by Eli Lilly and Company as Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. An ongoing phase II clinical trial in Italy recently reported almost double overall survival rates when ramucirumab was added to gemcitabine in second-line mesothelioma treatment. “These positive data may be the beginning to change the clinical practice in...
Source: Asbestos and Mesothelioma News - June 9, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

COVID-19 Closures Accelerate Asbestos Abatement in Schools
The COVID-19 pandemic closed educational institutions everywhere, but it also opened a door to the acceleration of vitally important asbestos abatement in schools where children would have been in attendance. Business has been booming. “It does look like a lot of schools took advantage of it [the closing of facilities],” Brent Kynoch, managing director of the Environmental Information Association, told The Mesothelioma Center at Asbestos.com. “They may have had work contracted for later in the summer, but just said, ‘Let’s get started with it now, and get it done.’ They understood the im...
Source: Asbestos and Mesothelioma News - June 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Health Experts Criticize EPA ’s Asbestos Draft Risk Evaluation
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - June 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab Phase III Trial Could Change Mesothelioma Care
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - May 28, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Specialist Brings HIPEC Expertise to Stanford
Surgical oncologist and mesothelioma specialist Dr. Byrne Lee spent close to a decade in Southern California, building a well-respected peritoneal surface malignancy program at City of Hope Comprehensive Cancer Center. He wants to build a bigger and better one now — second to none — almost 400 miles away. The quest is well underway. Lee, 45, joined the renowned Stanford Cancer Institute in October 2019 with a well-defined vision: Helping an elite academic institution become even better with a program for a previously underserved population. “I had a great career in Los Angeles. I’m proud of that pro...
Source: Asbestos and Mesothelioma News - May 26, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Ends Talc-Based Baby Powder Sales in US, Canada
Johnson & Johnson announced Tuesday that it will stop selling its iconic, talc-based baby powder, the target of thousands of lawsuits claiming that its talc was contaminated with asbestos, which led to cancers such as mesothelioma and ovarian cancer. The company said the stoppage is only in the United States and Canada, citing a decline in consumer demand and “misinformation” about the safety of the product. “Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product...
Source: Asbestos and Mesothelioma News - May 20, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Tests Find Asbestos-Contaminated Talc in Eyeshadow
The Scientific Analytical Institute in Greensboro, North Carolina, recently uncovered asbestos-contaminated talc in two new eyeshadow makeup products sold online on sites like Amazon and eBay. Its findings were the latest example in a growing list of talc-based cosmetic products found to contain toxic asbestos. Scientific Analytical Institute found asbestos fibers in 40% of the shades tested in Jmkcoz 120 Colors Eyeshadow Palette. It found traces of asbestos in 20% of the shades tested in the Beauty Glazed Gorgeous Me Eye Shadow Tray Palette. The results were released by the Environmental Working Group in Washington, D.C.,...
Source: Asbestos and Mesothelioma News - May 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Libby Protects Those with Asbestos Disease from COVID-19
No town in America has a higher percentage of asbestos-related lung disease — and resulting respiratory issues — than Libby, Montana, making its population uniquely vulnerable to the COVID-19 pandemic. Yet no town has responded to the threat so effectively. The home of the longest-running man-made environmental disaster in U.S. history — the mining of toxic asbestos for 70 years — has refused to let COVID-19 dictate who lives and who dies. The Center for Asbestos Related Disease, also known as CARD, has stepped up and taken charge. “We can’t afford to let the virus get loose here because...
Source: Asbestos and Mesothelioma News - May 13, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Report Finds Asbestos, Other Risks in Military Family Housing
This report is not a surprise for any service member who has lived in some of the older, on-post housing, either in the U.S. or overseas,” said Aaron Munz, former U.S. Army captain and director of the Veterans Department at The Mesothelioma Center at Asbestos.com. “Unfortunately, the military continues to expose service members to potentially dangerous conditions by not allocating the required resources to ensure that our personnel and their families are provided with safe housing.” Military Housing Report Stems from Congressional Directive The Department of Defense Office of Inspector General released th...
Source: Asbestos and Mesothelioma News - May 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Latest Clinical Trial for Pleural Mesothelioma Opens in Georgia
This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orall...
Source: Asbestos and Mesothelioma News - May 6, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Asbestos Review Delayed Due to COVID-19 Pandemic
The U.S. Environmental Protection Agency postponed indefinitely a peer review of the recent asbestos risk evaluation draft done by its Science Advisory Committee on Chemicals. A peer review virtual meeting was scheduled for April 27-30, but several independent scientific experts on the panel are no longer available. A Bloomberg Law article published this week explained that several health professionals serving on the committee could not attend because they needed to “give their full attention to the coronavirus crisis.” No date for the rescheduling was announced. “The agency believes that rescheduling for...
Source: Asbestos and Mesothelioma News - April 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

UK Oncologist Proposes Novel Treatment for Mesothelioma
Medical oncologist Dr. Angus Dalgleish never did like standard of care treatment for pleural mesothelioma cancer, even when he reluctantly recommended it in the past. He believes now there is something better. Dalgleish, of St. George’s Hospital, University of London, recently published a case report detailing a novel treatment regimen that turned a six-month life expectancy for one patient into a six-year survival. The treatment involved a series of anti-inflammatories that included low-dose naltrexone, vitamin D3 supplements and the vaccine IMM-101, which heightens a patient’s own immune response. “Init...
Source: Asbestos and Mesothelioma News - April 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Duke Study Challenges Mesothelioma Chemotherapy Practices
Neoadjuvant chemotherapy — often used before aggressive surgery — has shown no definitive survival benefit for patients with pleural mesothelioma cancer, according to a recent study at the Duke University Medical Center. The study strengthened the growing belief among mesothelioma specialists that the combination of chemotherapy drugs cisplatin and pemetrexed might be a more effective treatment after surgery than before. “I think the study provides a little more evidence to support what those of us were seeing, that (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - April 16, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

COVID-19 Pandemic Delays Mesothelioma Clinical Trials
Medical centers across the country have slowed or stopped the enrollment of new patients in mesothelioma clinical trials because of the all-consuming COVID-19 pandemic. The pause in enrollment options could be critical for newly diagnosed patients with pleural mesothelioma, whose life expectancy is often just six to 12 months. Clinical trials are research studies where patients can find cutting-edge treatments not yet approved by the U.S. Food and Drug Administration. Those experimental treatments go beyond standard of care, which generally has not been effective for this rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - April 9, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Finds Asbestos Use Poses Risk to Chloralkali Workers
The U.S. Environmental Protection Agency released an asbestos draft risk evaluation Monday that found serious health dangers to workers in the chloralkali industry, the country’s last remaining user of raw asbestos. There is an “unreasonable risk to workers, occupational non-users, consumers and bystanders” the EPA found when evaluating several asbestos products still being imported and used today. The draft risk evaluation was an initial review of asbestos by the EPA under the amended Toxic Substances Control Act (TSCA). “It is being disseminated for peer review purposes and is not final,” an...
Source: Asbestos and Mesothelioma News - April 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Latest Study Reinforces Cosmetic Talc, Mesothelioma Link
Evidence continues to mount that prolonged exposure to cosmetic talcum powder contaminated by asbestos fibers is causing mesothelioma cancer. Individuals using cosmetic talc regularly may be putting themselves at higher risk, according to doctors at Peninsula Pathology Associates in Newport News, Virginia. They recently completed the most extensive case study to date on the topic. Mesothelioma is an aggressive cancer caused primarily by the inhalation or ingestion of asbestos fibers. Peninsula’s study involved 75 mesothelioma patients — including 64 women — who believed their only exposure to asbestos was...
Source: Asbestos and Mesothelioma News - April 1, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Florida Legislation Protects Firefighters from Mesothelioma
The Florida Legislature has passed a bill designed to better protect its firefighters from cancer-causing contaminants, including toxic asbestos. By approving the legislation, Florida joined a growing number of states that have passed laws in recent years to help firefighters combat occupational hazards they face every day. The Firefighter Cancer Decontamination Equipment Grant Program in Florida will provide funding for departments to procure supplies, equipment and add additional training that should reduce exposure to hazardous pollutants. It includes all fire departments across the state, from large municipal entities...
Source: Asbestos and Mesothelioma News - March 30, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Survivors Face Critical COVID-19 Challenges
As the U.S. comes to grips with the challenges of the COVID-19 pandemic, mesothelioma cancer survivors face additional hurdles, including difficulty receiving care. Patients currently undergoing treatment for cancer and those who are immunocompromised are at greater risk of serious health issues if they contract COVID-19, according to the Centers for Disease Control and Prevention. “Cancer patients are a high-risk group and should be extra vigilant in terms of isolation precautions. They should follow the medical authorities’ instructions,” Dr. Ory Wiesel, a thoracic surgeon at Maimonides Medical Center ...
Source: Asbestos and Mesothelioma News - March 26, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

US Asbestos Imports Dropped Significantly in 2019
Raw asbestos imported to the United States dropped significantly in 2019, according to the recently released U.S. Geological Survey Mineral Commodity Summaries report. The U.S. imported an estimated 100 metric tons of asbestos last year. It’s the smallest amount since records were first kept in 1910, long before the mineral became a major part of the construction industry in America. That number is in sharp contrast to the 681 metric tons imported in 2018. All imported asbestos went to the chloralkali industry — for the second consecutive year — to use in the manufacturing of semipermeable diaphragms for ...
Source: Asbestos and Mesothelioma News - March 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Promising Data Supports Curcumin Treatment for Mesothelioma
The plant-based substance curcumin could soon be included in the multidisciplinary treatment of malignant mesothelioma, according to a recent multicenter, international study review. Curcumin, an active compound found in the common culinary spice turmeric, has been used for decades by some as an anti-inflammatory, complementary medicine for many ailments. It may soon take a more prominent role with mesothelioma, an aggressive cancer with no definitive cure. “Our hope is that, in the not-too-distant future, it could be part of new therapeutic strategies for mesothelioma,” Dr. Antonio Giordano, director of Sbarro...
Source: Asbestos and Mesothelioma News - March 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

UPenn Research with Mesothelioma Blood Test Shows Promise
Scientist Ian Blair at the University of Pennsylvania School of Medicine believes his team is close to identifying the variant of a blood-based biomarker that could diagnose asbestos disease in its earliest stages. If successful, it could clear the path to a more treatable — and potentially curable — stage of malignant mesothelioma cancer. “This could be a big deal. We’re trying to become the first,” Blair told The Mesothelioma Center at Asbestos.com. “We hope to have it within the year.” The potential breakthrough involves the HMGB1 (High-Mobility Group Box 1) chromosomal protein...
Source: Asbestos and Mesothelioma News - March 16, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Clinical Trial Testing New INBRX-109 Antibody
A new clinical trial is testing an innovative approach to immunotherapy that could change the way antibodies target pleural mesothelioma tumors. Researchers at eight cancer centers across the U.S. are examining the safety and efficacy of INBRX-109, a unique antibody structure developed to bind with and destroy mesothelioma tumor cells without harming healthy tissue. Enrollment for mesothelioma patients is ongoing for the second stage of the first-in-humans trial. Safety and efficacy reports are expected in the second quarter of 2020. The first stage of the trial reached its endpoint with no reports of toxicity or intoleran...
Source: Asbestos and Mesothelioma News - March 12, 2020 Category: Environmental Health Authors: Walter Pacheco Source Type: news

FDA Tests Find Asbestos in Nine Cosmetic-Talc Products
The U.S. Food and Drug Administration found asbestos-contaminated talc in nine of the 52 cosmetic products tested during its year-long study released this week. The products with asbestos were recalled at various times throughout the past year when individual results were obtained and the public was notified. Monday’s announcement by the FDA was labeled a Constituent Update and Final Report. It also included those products that showed no trace of contamination. AMA Analytical Services Inc. in Lanham, Maryland, performed all testing for the FDA, using polarized light microscopy and transmission electron microscopy, cu...
Source: Asbestos and Mesothelioma News - March 10, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Coronavirus Postpones Mesothelioma Symposium
The Mesothelioma Applied Research Foundation has postponed its annual International Symposium on Malignant Mesothelioma next month because of the COVID-19 virus, commonly known as the novel coronavirus. The event is the largest gathering of the mesothelioma community each year. It was scheduled for April 6-7 in San Antonio, Texas. Officials with the Mesothelioma Applied Research Foundation announced the postponement Wednesday but has not yet rescheduled. Each year, the symposium brings together patients, caregivers, advocates, attorneys, financial consultants, doctors and nurses from various disciplines. The goal is to edu...
Source: Asbestos and Mesothelioma News - March 5, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study to Clarify Radiation Benefits in Mesothelioma Patients
An upcoming phase III clinical trial involving the National Cancer Institute should clarify the still-debatable benefits of using radiotherapy in combination with aggressive surgery for patients with pleural mesothelioma. The trial will be the first multicenter, randomized study measuring both safety and potential survival benefits of intensity-modulated radiation therapy (IMRT) and pencil-beam scanning with pleurectomy and decortication surgery and chemotherapy. The trial is sponsored by NRG Oncology and will involve several mesothelioma specialty centers across the country. The goal is to enroll a combined 150 patients. ...
Source: Asbestos and Mesothelioma News - March 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Revlon Named in Talc-Mesothelioma Lawsuit
Revlon Inc. on Tuesday became the latest corporation hit with a lawsuit alleging asbestos-contaminated talc in its cosmetic products caused mesothelioma cancer in a woman. A Maryland couple filed the lawsuit in New York state court. Laura McDaniel believes her diagnosis of mesothelioma in January stems from her father’s earlier employment with Revlon, the multinational skin care, fragrance and cosmetics giant headquartered in New York City. She is seeking $20 million in compensatory damage and $40 million in punitive damages. Husband Edward McDaniel wants $5 million for mental anguish and loss of companionship. More ...
Source: Asbestos and Mesothelioma News - February 26, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Clinical Trial Involves Immunotherapy Before Surgery
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - February 24, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Detection May Come Earlier with Liquid Biopsy
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - February 18, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Gene Therapy Trial Shows ‘Real Potential’
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - February 17, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Therapy for Mesothelioma Has ‘Real Potential’
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - February 17, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - February 12, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news